TD Cowen raised the firm’s price target on HCA Healthcare to $326 from $292 and keeps an Outperform rating on the shares. The analyst said following its strong results they uodated their model which now assumes a peak 10x 2024 EV/EBITDA-NCI target multiple, as we retain conservatism with respect to a possible $0.5b Medicaid redetermination payor-mix tailwind by 2024 year-end.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HCA:
